| 151 |
23433665 | Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. | 2013 Aug 4 |
1 |
| 152 |
23466625 | Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. | 2013 Jul |
1 |
| 153 |
23569389 | Systematic review of dasatinib in chronic myeloid leukemia. | 2013 |
1 |
| 154 |
23576564 | Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. | 2013 Jun 1 |
2 |
| 155 |
23630094 | Chromothripsis in Hodgkin lymphoma. | 2013 Aug |
1 |
| 156 |
23701117 | A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines. | 2013 Dec |
1 |
| 157 |
23715577 | Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. | 2013 Jul 1 |
1 |
| 158 |
23815902 | [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia]. | 2013 Jun |
4 |
| 159 |
23816609 | Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. | 2013 Oct |
7 |
| 160 |
23906052 | New insights into biology of chronic myeloid leukemia: implications in therapy. | 2013 Sep |
1 |
| 161 |
23942795 | The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. | 2013 Dec |
4 |
| 162 |
24007855 | Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. | 2013 Sep 5 |
1 |
| 163 |
24072218 | Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. | 2013 |
1 |
| 164 |
24095296 | A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. | 2013 Dec |
1 |
| 165 |
24130846 | A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. | 2013 |
1 |
| 166 |
24137941 | [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects]. | 2013 |
1 |
| 167 |
24155950 | Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. | 2013 |
1 |
| 168 |
24236021 | Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. | 2013 |
1 |
| 169 |
24240798 | Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. | 2013 |
2 |
| 170 |
24385789 | Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. | 2013 Jun |
1 |
| 171 |
24729782 | Enhanced Ca2+Entry and Tyrosine Phosphorylation Mediate Nanostructure-Induced Endothelial Proliferation. | 2013 Oct 6 |
1 |
| 172 |
21717440 | Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. | 2012 Jan 15 |
1 |
| 173 |
21751967 | Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib. | 2012 Jan |
1 |
| 174 |
21844872 | Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. | 2012 Feb |
1 |
| 175 |
21874302 | The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. | 2012 Feb |
1 |
| 176 |
22089930 | Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. | 2012 Feb |
1 |
| 177 |
22160483 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | 2012 Feb 2 |
2 |
| 178 |
22233429 | Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2012 Feb 1 |
4 |
| 179 |
22262141 | Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. | 2012 Feb |
1 |
| 180 |
22262776 | Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. | 2012 Mar 8 |
1 |
| 181 |
22285209 | Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. | 2012 Feb |
1 |
| 182 |
22344285 | Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform. | 2012 Apr |
2 |
| 183 |
22419518 | Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. | 2012 Sep 15 |
1 |
| 184 |
22428569 | Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. | 2012 Jun |
1 |
| 185 |
22493660 | Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. | 2012 |
1 |
| 186 |
22538170 | Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. | 2012 Jun 15 |
1 |
| 187 |
22554713 | Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. | 2012 Oct 28 |
3 |
| 188 |
22587422 | Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. | 2012 May 15 |
2 |
| 189 |
22591714 | The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. | 2012 Jul 3 |
1 |
| 190 |
22689211 | Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification. | 2012 Aug |
3 |
| 191 |
22815843 | Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. | 2012 |
1 |
| 192 |
22846973 | Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. | 2012 |
1 |
| 193 |
22874537 | Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes. | 2012 Nov |
1 |
| 194 |
22956142 | An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. | 2012 |
2 |
| 195 |
22985168 | Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. | 2012 Sep 17 |
2 |
| 196 |
22992064 | Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. | 2012 Nov |
1 |
| 197 |
23010482 | Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. | 2012 Nov |
1 |
| 198 |
23049975 | c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. | 2012 |
2 |
| 199 |
23090888 | Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. | 2012 Nov |
1 |
| 200 |
23138519 | Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. | 2012 Dec |
2 |